Retrospective study shows enhanced outcomes in unresectable hepatocellular carcinoma with combined treatment.
Key Points
This research aims to evaluate the effectiveness and safety of HAIC combined with lenvatinib and pembrolizumab in treating unresectable hepatocellular carcinoma.
Retrospective analysis of treatment-naïve patients with uHCC (BCLC stage B/C) at a single center from January 2019 to January 2024.
Patients received HAIC combined with lenvatinib and pembrolizumab, with outcomes assessed using RECIST 1.1 and mRECIST.
Overall survival (OS) and progression-free survival (PFS) were analyzed, along with treatment-related adverse events.
Median PFS was 9.63 months (95% CI, 6.59–12.68).
Median OS was 27.50 months (95% CI, 18.17–36.83).
Overall response rate (ORR) was 47.0% (RECIST 1.1) and 66.7% (mRECIST), with a disease control rate (DCR) of 90.9% across both criteria.